We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.01%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$111M
AUM Growth
+$2.3M
Cap. Flow
+$4.8M
Cap. Flow %
4.31%
Top 10 Hldgs %
45.14%
Holding
70
New
3
Increased
23
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
BIVV
Bioverativ Inc. Common Stock
BIVV
+$648K
2
UTHR icon
United Therapeutics
UTHR
+$525K
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$509K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$340K
5
SGEN
Seagen Inc. Common Stock
SGEN
+$316K

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$613K
2
MYGN icon
Myriad Genetics
MYGN
+$527K
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$404K
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$220K
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$140K

Sector Composition

Rank Sector Weight
1 Healthcare 73.61%
2 Miscellaneous 26.05%
3 Real Estate 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIB icon
1
ProShares Ultra NASDAQ Biotechnology
BIB
$105M
$7.99M 7.17%
130,500
– –
BMY icon
2
Bristol-Myers Squibb
BMY
$137B
$5.74M 5.15%
90,000
– –
XBI icon
3
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$5.63M 5.05%
65,000
– –
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$31.7B
$5.58M 5%
47,459
-1,636
-3% -$140K
MRK icon
5
Merck
MRK
$369B
$5.36M 4.81%
87,718
– –
ALXN
6
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$4.91M 4.41%
35,000
– –
IBB icon
7
iShares Biotechnology ETF
IBB
$10.8B
$4.17M 3.74%
37,500
– –
AZN icon
8
AstraZeneca
AZN
$255B
$4.07M 3.65%
60,000
– –
PFE icon
9
Pfizer
PFE
$160B
$4.01M 3.6%
118,364
– –
BMY icon
10
CALL
Bristol-Myers Squibb
BMY
$137B
$2.87M 2.57%
45,000
– –
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$139B
$2.78M 2.49%
18,274
-720
-4% -$108K
NKTR icon
12
Nektar Therapeutics
NKTR
$2.55B
$2.5M 2.25%
6,955
+475
+7% +$149K
ALKS icon
13
Alkermes
ALKS
$8.2B
$2.45M 2.2%
48,244
+5,621
+13% +$301K
GSK icon
14
GSK
GSK
$101B
$2.44M 2.19%
48,000
– –
CELG
15
DELISTED
Celgene Corp
CELG
$2.36M 2.12%
16,177
+1,833
+13% +$250K
INCY icon
16
Incyte
INCY
$25.9B
$2.35M 2.11%
20,148
+2,316
+13% +$293K
MTD icon
17
Mettler-Toledo International
MTD
$28.2B
$2.25M 2.02%
3,594
– –
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
$2.25M 2.01%
41,263
+6,170
+18% +$316K
IONS icon
19
Ionis Pharmaceuticals
IONS
$10.4B
$2.24M 2.01%
44,183
+316
+0.7% +$16.6K
ILMN icon
20
Illumina
ILMN
$34.4B
$2.24M 2.01%
11,550
+1,357
+13% +$253K
AGIO icon
21
Agios Pharmaceuticals
AGIO
$2.05B
$2.23M 2%
33,347
+3,865
+13% +$232K
AMGN icon
22
Amgen
AMGN
$236B
$2.13M 1.91%
11,406
+1,585
+16% +$281K
RXDX
23
DELISTED
Ignyta, Inc.
RXDX
$2.11M 1.89%
170,500
– –
BIIB icon
24
Biogen
BIIB
$32.7B
$2.09M 1.88%
6,687
+910
+16% +$269K
REGN icon
25
Regeneron Pharmaceuticals
REGN
$83.2B
$2.04M 1.83%
4,561
+29
+0.6% +$13.8K
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2017 Portfolio in Review

As of Q3 2017, Opus Point Partners Management held 70 positions worth $111M, up 2.1% from $109M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Opus Point Partners Management deployed $4.8M of net new capital in Q3 2017, opening 3 new positions and adding to 23 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $140K trimmed.

  • Opus Point Partners Management's largest Q3 2017 buy was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.
  • Opus Point Partners Management added most to Ultragenyx Pharmaceutical in Q3 2017, an estimated $340K increase.
  • Opus Point Partners Management's biggest Q3 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $140K.
  • Opus Point Partners Management fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $613K.
  • Opus Point Partners Management's ten largest holdings make up 45% of its $111M portfolio in Q3 2017.
  • Opus Point Partners Management opened 3 new positions and closed 7 in Q3 2017.
  • Opus Point Partners Management's portfolio value rose 2.1% quarter-over-quarter to $111M.

Based on Opus Point Partners Management's 13F filing for Q3 2017, filed 14 Nov 2017.